PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 145 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.11 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $396,043 | +12.8% | 14,339 | -8.2% | 0.00% | – |
| Q1 2023 | $351,226 | +191.2% | 15,617 | +41.3% | 0.00% | – |
| Q4 2022 | $120,621 | -84.2% | 11,056 | -90.2% | 0.00% | -100.0% |
| Q4 2018 | $762,000 | -50.0% | 113,155 | -23.6% | 0.00% | 0.0% |
| Q3 2018 | $1,524,000 | +53.2% | 148,076 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $995,000 | -18.9% | 148,076 | +3.7% | 0.00% | 0.0% |
| Q1 2018 | $1,227,000 | – | 142,834 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |